The Accelerated Access Collaborative

Executive Summary

• The Accelerated Access Collaborative (AAC) is the decision-making body for the Accelerated Access Pathway (AAP) which arose from the Government’s Accelerated Access Review (AAR)
• The Pathway provides a route and interim funding to enable widespread reimbursement of proven and cost-effective pharmaceuticals and medical devices
• Products selected for this route are expected to achieve a minimum of cost-neutrality, and ideally savings, a year after launch via the AAP
• Only licensed products (i.e. those with CE marking or marketing authorisation) are eligible for the scheme